Inipharm’s $35 Million Series A Financing


Fenwick & West LLP advised Inipharm on the deal.

Inipharm, a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases, announced its $35 million Series A financing.

Inipharm plans to use the Series A funding to support the advancement of its lead program through IND filing and into clinical trials.

The Fenwick transaction team was led by corporate partner Matthew Rossiter (Picture) and associates Christine Chen, Shweta Kumar and Monica Zwolinski.

Involved fees earner: Christine Chen – Fenwick & West LLP; Shweta Kumar – Fenwick & West LLP; Matthew Rossiter – Fenwick & West LLP; Monica Zwolinski – Fenwick & West LLP;

Law Firms: Fenwick & West LLP;

Clients: Inipharm;

Author: Ambrogio Visconti